Pathogenicity and drug resistance in Candida albicans and other yeast species
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Pathogenic yeasts from the genus Candida can cause serious infection in humans particularly, in immunocompromised patients and are now recognized as major agents of hospital acquired (nosocomial) infections. In the recent years, there has been a marked increase in the incidence of treatment failures in candidiasis patients receiving long-term antifungal therapy, which has posed a serious problem in its successful use in chemotherapy. Candida cells acquire drug resistance (MDR) during the course of the treatment. The mechanisms of resistance to azole antifungal agents have been elucidated in Candida species and can be mainly categorized as (i) changes in the cell wall or plasma membrane, which lead to impaired drug (azole) uptake; (ii) alterations in the affinity of the drug target Erg11p (lanosterol 14∝-demethylase) especially to azoles or in the cellular content of Erg11p due to target site mutation or overexpression of the ERG11 gene; and (iii) the efflux of drugs mediated by membrane transport proteins belonging to the ATP-binding cassette (ABC) transporters, namely CDR1 and CDR2 or to the major facilitator superfamily (MFS) transporter, CaMDR1 . Many such manifestations are associated with the formation of Candida biofilms including those occurring on devices like indwelling intravascular catheters. Biofilm-associated Candida show uniform resistance to a wide spectrum of antifungal drugs. A combination of different resistance mechanisms is responsible for drug resistance in clinical isolates of Candida species.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biofilms: Survival Mechanisms of Clinically Relevant Microorganisms
Donlan, R. M., & Costerton, J. W. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.2.167-193.2002 · Cited by 6,644 · cited 1×
“Growth rate could therefore be an important modulator of drug activity in biofilms [56, 60].”
Walker, J. E., Saraste, M., Runswick, M. J., & Gay, N. J. (1982) · The EMBO Journal · doi:10.1002/j.1460-2075.1982.tb01276.x · Cited by 5,312 · cited 1×
“For example, NBDs of ABC transporters have a b-sheet sub-domain containing the typical Walker A and Walker B motifs, as an essential feature of all ATP requiring enzymes [122], along with an a-helical sub-domain that possesses the conserved ABC signature sequence.”
Romani, L. (2011) · Nature Reviews Immunology · doi:10.1038/nri2939 · Cited by 1,793
Candida albicans Secreted Aspartyl Proteinases in Virulence and Pathogenesis
Naglik, J. R., Challacombe, S. J., & Hube, B. (2003) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.67.3.400-428.2003 · Cited by 1,179 · cited 1×
“albicans is due to aspartyl proteinase enzymes constituting a family of enzymes (SAP: secreted aspartyl proteinases) whose expression depends on both the yeast strain and the environment [12, 16].”
Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937
Sanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815
The Epidemiology of Hematogenous Candidiasis Caused by Different Candida Species
Abi‐Said, D., Anaissie, E., Uzun, O., Raad, I., Pinzcowski, H., & Vartivarian, S. (1997) · Clinical Infectious Diseases · doi:10.1086/513663 · Cited by 755 · cited 2×
“glabrata, was reported [143], some studies reported a reduction in prevalence of C.”
White, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612
Viscoli, C., Girmenia, C., Marinus, A., Collette, L., Martino, P., Vandercam, B., Doyen, C., Lebeau, B., Spence, D., Krcmery, V., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/514731 · Cited by 601 · cited 1×
“glabrata was much more frequent in patients with haematological malignancies than in those with solid tumors [146].”
Prasad, R., De Wergifosse, P., Goffeau, A., & Balzi, E. (1995) · Current Genetics · doi:10.1007/bf00352101 · Cited by 486
Self-citation
Cited by
Skin tissue engineering — In vivo and in vitro applications
Groeber, F., Holeiter, M., Hampel, M., Hinderer, S., & Schenke-Layland, K. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.01.005 · Cited by 633
Campoy, S., & Adrio, J. L. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.019 · Cited by 511
Lu, S.-Y. (2021) · Journal of Fungi · doi:10.3390/jof7070555 · Cited by 118
Li, Y., Chang, W., Zhang, M., Li, X., Jiao, Y., & Lou, H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0128693 · Cited by 79
“The emergence of drug resistance leads to more nosocomial infections and costs [7], which highlights the need of novel and effective antifungal therapeutics.”
BackgroundXie, J. L., Qin, L., Miao, Z., Grys, B. T., Diaz, J. D. L. C., Ting, K., Krieger, J. R., Tong, J., Tan, K., Leach, M. D., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00547-y · Cited by 60
Metadata
- Authors
- Mishra, N., Prasad, T., Sharma, N., Payasi, A., Prasad, R., Gupta, D., & Singh, R.
- Venue
- Acta Microbiologica et Immunologica Hungarica
- Publisher
- Akademiai Kiado Zrt.
- Published
- 2007-09-01
- Volume
- 54
- Issue
- 3
- Pages
- 201-235
- ISSN
- 1217-8950 (ISSN-L)
- 1588-2640
- OpenAlex
- W2007451007
- Cited by
- 168
- References
- 21
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pathogenicity and drug resistance in Candida albicans and other yeast species. https://app.cochat.ai/papers/10.1556/amicr.54.2007.3.1
- The paper
- Mishra, N., Prasad, T., Sharma, N., Payasi, A., Prasad, R., Gupta, D., & Singh, R. (2007). Pathogenicity and drug resistance in Candida albicans and other yeast species. Acta Microbiologica et Immunologica Hungarica. https://doi.org/10.1556/amicr.54.2007.3.1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.